Twist Bioscience Corporation (TWST)

Market Cap	2.02B
Revenue (ttm)	347.68M
Net Income (ttm)	-191.15M
Shares Out	59.92M
EPS (ttm)	-3.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,376,454
Open	32.50
Previous Close	33.57
Day's Range	32.38 - 33.99
52-Week Range	27.12 - 56.84
Beta	2.42
Analysts	Buy
Price Target	49.10 (+45.78%)
Earnings Date	Aug 4, 2025

About ACCD

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 31, 2018
• Employees: 923
• Stock Exchange: NASDAQ
• Ticker Symbol: TWST
• Website: https://www.twistbioscience.com

Financial Performance

In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $49.1, which is an increase of 45.78% from the latest price.

Price Target

$49.1

(45.78% upside)

Analyst Consensus: Buy